Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Treasury Shares: 2020-2024

  • Maravai Lifesciences Holdings' Treasury Shares rose 101.47% to $7.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $7.9 million, marking a year-over-year increase of 101.47%. This contributed to the annual value of $7.9 million for FY2024, which is 101.47% up from last year.
  • Maravai Lifesciences Holdings' Treasury Shares amounted to $7.9 million in Q4 2024, which was up 101.47% from $3.9 million recorded in Q4 2023.
  • Maravai Lifesciences Holdings' Treasury Shares' 5-year high stood at $7.9 million during Q4 2024, with a 5-year trough of $159,000 in Q4 2021.
  • In the last 3 years, Maravai Lifesciences Holdings' Treasury Shares had a median value of $3.9 million in 2023 and averaged $4.4 million.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Treasury Shares crashed by 54.44% in 2021, and later soared by 737.11% in 2022.
  • Maravai Lifesciences Holdings' Treasury Shares (Quarterly) stood at $349,000 in 2020, then crashed by 54.44% to $159,000 in 2021, then soared by 737.11% to $1.3 million in 2022, then spiked by 196.32% to $3.9 million in 2023, then spiked by 101.47% to $7.9 million in 2024.
  • Its Treasury Shares stands at $7.9 million for Q4 2024, versus $3.9 million for Q4 2023 and $1.3 million for Q4 2022.